How much did GeneReach Biotechnology achieve in EBIT for the current year?
In the current year, GeneReach Biotechnology has achieved an EBIT of -229.29 M TWD.
GeneReach Biotechnology EBIT 2024
GeneReach Biotechnology EBIT
-229.29 M TWD
Ticker
4171.TWO
ISIN
TW0004171004
In 2024, GeneReach Biotechnology's EBIT was -229.29 M TWD, a -195% increase from the 241.34 M TWD EBIT recorded in the previous year.
The GeneReach Biotechnology EBIT history
| YEAR | EBIT (undefined TWD) |
|---|---|
| 2023 | -229.29 |
| 2022 | 241.34 |
| 2021 | 482.35 |
| 2020 | 355.41 |
| 2019 | 111.94 |
| 2018 | 11.38 |
| 2017 | -21.42 |
| 2016 | -26.68 |
| 2015 | -26.95 |
| 2014 | -42.26 |
| 2013 | -57.83 |
| 2012 | -31.1 |
| 2011 | 3.87 |
| 2010 | 16.22 |
| 2009 | 5.55 |
GeneReach Biotechnology Revenue, EBIT, Net Income TW0004171004 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into GeneReach Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GeneReach Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GeneReach Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of GeneReach Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into GeneReach Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing GeneReach Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GeneReach Biotechnology’s growth potential.
GeneReach Biotechnology Revenue, EBIT and net profit per share
| Date | GeneReach Biotechnology Revenue | GeneReach Biotechnology EBIT | GeneReach Biotechnology Net Income |
|---|---|---|---|
| 2023 | 225.46 M undefined | -229.29 M undefined | -166.27 M undefined |
| 2022 | 750.02 M undefined | 241.34 M undefined | 221.34 M undefined |
| 2021 | 1.01 B undefined | 482.35 M undefined | 376.62 M undefined |
| 2020 | 857.03 M undefined | 355.41 M undefined | 257.28 M undefined |
| 2019 | 365.8 M undefined | 111.94 M undefined | 77.18 M undefined |
| 2018 | 187.42 M undefined | 11.38 M undefined | 28.57 M undefined |
| 2017 | 155.41 M undefined | -21.42 M undefined | -48.13 M undefined |
| 2016 | 150.27 M undefined | -26.68 M undefined | -38.66 M undefined |
| 2015 | 149.15 M undefined | -26.95 M undefined | -24.82 M undefined |
| 2014 | 133.65 M undefined | -42.26 M undefined | -30.43 M undefined |
| 2013 | 95.85 M undefined | -57.83 M undefined | -58 M undefined |
| 2012 | 99.58 M undefined | -31.1 M undefined | -23.35 M undefined |
| 2011 | 105.6 M undefined | 3.87 M undefined | 3.54 M undefined |
| 2010 | 82.18 M undefined | 16.22 M undefined | 13.04 M undefined |
| 2009 | 62.65 M undefined | 5.55 M undefined | 4.54 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2009 | 62.65 M TWD | 5.55 M TWD | 4.54 M TWD |
| 2010 | 82.18 M TWD | 16.22 M TWD | 13.04 M TWD |
| 2011 | 105.6 M TWD | 3.87 M TWD | 3.54 M TWD |
| 2012 | 99.58 M TWD | -31.1 M TWD | -23.35 M TWD |
| 2013 | 95.85 M TWD | -57.83 M TWD | -58 M TWD |
| 2014 | 133.65 M TWD | -42.26 M TWD | -30.43 M TWD |
| 2015 | 149.15 M TWD | -26.95 M TWD | -24.82 M TWD |
| 2016 | 150.27 M TWD | -26.68 M TWD | -38.66 M TWD |
| 2017 | 155.41 M TWD | -21.42 M TWD | -48.13 M TWD |
| 2018 | 187.42 M TWD | 11.38 M TWD | 28.57 M TWD |
| 2019 | 365.8 M TWD | 111.94 M TWD | 77.18 M TWD |
| 2020 | 857.03 M TWD | 355.41 M TWD | 257.28 M TWD |
| 2021 | 1.01 B TWD | 482.35 M TWD | 376.62 M TWD |
| 2022 | 750.02 M TWD | 241.34 M TWD | 221.34 M TWD |
| 2023 | 225.46 M TWD | -229.29 M TWD | -166.27 M TWD |
GeneReach Biotechnology stock margins TW0004171004 ·
The GeneReach Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GeneReach Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GeneReach Biotechnology.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the GeneReach Biotechnology's sales revenue. A higher gross margin percentage indicates that the GeneReach Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the GeneReach Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the GeneReach Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GeneReach Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GeneReach Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GeneReach Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
GeneReach Biotechnology Margin History
| GeneReach Biotechnology Gross margin | GeneReach Biotechnology Profit margin | GeneReach Biotechnology EBIT margin | GeneReach Biotechnology Profit margin |
|---|---|---|---|
| 2023 | 12.23 % | -101.7 % | -73.75 % |
| 2022 | 65.34 % | 32.18 % | 29.51 % |
| 2021 | 73.81 % | 47.66 % | 37.21 % |
| 2020 | 74.14 % | 41.47 % | 30.02 % |
| 2019 | 82.57 % | 30.6 % | 21.1 % |
| 2018 | 79.69 % | 6.07 % | 15.24 % |
| 2017 | 80.7 % | -13.78 % | -30.97 % |
| 2016 | 80.74 % | -17.75 % | -25.73 % |
| 2015 | 78.91 % | -18.07 % | -16.64 % |
| 2014 | 80.23 % | -31.62 % | -22.77 % |
| 2013 | 68.9 % | -60.33 % | -60.52 % |
| 2012 | 78.14 % | -31.23 % | -23.45 % |
| 2011 | 83.62 % | 3.67 % | 3.35 % |
| 2010 | 88.7 % | 19.74 % | 15.87 % |
| 2009 | 86.77 % | 8.86 % | 7.24 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2009 | 86.77 % | 8.86 % | 7.24 % |
| 2010 | 88.7 % | 19.74 % | 15.87 % |
| 2011 | 83.62 % | 3.67 % | 3.35 % |
| 2012 | 78.14 % | -31.23 % | -23.45 % |
| 2013 | 68.9 % | -60.33 % | -60.52 % |
| 2014 | 80.23 % | -31.62 % | -22.77 % |
| 2015 | 78.91 % | -18.07 % | -16.64 % |
| 2016 | 80.74 % | -17.75 % | -25.73 % |
| 2017 | 80.7 % | -13.78 % | -30.97 % |
| 2018 | 79.69 % | 6.07 % | 15.24 % |
| 2019 | 82.57 % | 30.6 % | 21.1 % |
| 2020 | 74.14 % | 41.47 % | 30.02 % |
| 2021 | 73.81 % | 47.66 % | 37.21 % |
| 2022 | 65.34 % | 32.18 % | 29.51 % |
| 2023 | 12.23 % | -101.7 % | -73.75 % |
GeneReach Biotechnology Aktienanalyse
What does GeneReach Biotechnology do?
GeneReach Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing GeneReach Biotechnology's EBIT
GeneReach Biotechnology's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of GeneReach Biotechnology's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
GeneReach Biotechnology's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in GeneReach Biotechnology’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about GeneReach Biotechnology stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company GeneReach Biotechnology.
How has the EBIT of GeneReach Biotechnology developed in recent years?
The EBIT of GeneReach Biotechnology has increased by -195.004% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company GeneReach Biotechnology?
The EBIT of GeneReach Biotechnology is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does GeneReach Biotechnology pay?
Over the past 12 months, GeneReach Biotechnology paid a dividend of 1.2 TWD . This corresponds to a dividend yield of about 4.09 %. For the coming 12 months, GeneReach Biotechnology is expected to pay a dividend of 1.2 TWD.
What is the dividend yield of GeneReach Biotechnology?
The current dividend yield of GeneReach Biotechnology is 4.09 %.
When does GeneReach Biotechnology pay dividends?
GeneReach Biotechnology pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of GeneReach Biotechnology?
GeneReach Biotechnology paid dividends every year for the past 2 years.
What is the dividend of GeneReach Biotechnology?
For the upcoming 12 months, dividends amounting to 1.2 TWD are expected. This corresponds to a dividend yield of 4.09 %.
In which sector is GeneReach Biotechnology located?
GeneReach Biotechnology is assigned to the 'Health' sector.
Wann musste ich die Aktien von GeneReach Biotechnology kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of GeneReach Biotechnology from 9/4/2023 amounting to 1.2 TWD, you needed to have the stock in your portfolio before the ex-date on 7/28/2023.
When did GeneReach Biotechnology pay the last dividend?
The last dividend was paid out on 9/4/2023.
What was the dividend of GeneReach Biotechnology in the year 2023?
In the year 2023, GeneReach Biotechnology distributed 3.636 TWD as dividends.
In which currency does GeneReach Biotechnology pay out the dividend?
The dividends of GeneReach Biotechnology are distributed in TWD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von GeneReach Biotechnology
Our stock analysis for GeneReach Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GeneReach Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- GeneReach Biotechnology Revenue
- GeneReach Biotechnology Net Income
- GeneReach Biotechnology P/E
- GeneReach Biotechnology P/S
- GeneReach Biotechnology EBIT
- GeneReach Biotechnology Dividend
- GeneReach Biotechnology Stocks
- GeneReach Biotechnology Market capitalization
- GeneReach Biotechnology Debt
- GeneReach Biotechnology Liabilities
- GeneReach Biotechnology Equity
- GeneReach Biotechnology AAQS
- GeneReach Biotechnology Employees
- GeneReach Biotechnology ROE
- GeneReach Biotechnology ROA
- GeneReach Biotechnology ROCE